Vesicular Stomatitis Virus-Ebola Virus vaccine — known as VSV-EBOV — is an experimental vaccine for protecting against Ebola virus disease. It was created by scientists at the National Microbiology Laboratory in Winnipeg, Canada. The Public Health Agency of Canada owns the vaccine and the patent on it, and licensed it to a small company called NewLink Genetics in 2010 so that the vaccine could be developed, approved by regulatory authorities, and made available for use; NewLink in turn licensed the rights to Merck in 2014.
VSV-EBOV is a recombinant, replication-competent vaccine. It consists of a vesicular stomatitis virus, which has been genetically engineered to express Ebola glycoproteins so as to provoke an immune response against the complete Ebola virus. The vaccine variant known as rVSV-ZEBOV, rVSV-ZEBOV-GP, VSVΔG-ZEBOV, or BPSC1001 expresses glycoproteins of the Zaire ebolavirus or ZEBOV, the species causing the highest mortality rate among the ebolaviruses, while rVSV-MARV or rVSV-MARV-GP expresses those of the closely related Marburg filovirus or MARV.As of January 2016 phase III clinical trials were ongoing.